Jiudian Pharmaceutical have drug license of Ebastine oral solution from NMPA

Release time:

2024-02-01 12:36

Source:

At the beginning of 2024, PudaoPharma, which is wholly-owned subsidiary of Jiudian Pharmaceutical, had drug license of Ebastine oral solution from NMPA. PudaoPharma is the first enterprise to obtain this dosage form license of Ebastine in China.

Jiudian Pharmaceutical also the MAH of Ebastine tablets. There are four MAH of it in China at present.

The annual marketing turnover of tablets is 550 million RMB in public hospital in 2022.

Hunan Jiudian Pharmaceutical have Market Authorization of dapoxetine hydrochloride, celecoxib and Nicorandil API from NMPA

Hunan Jiudian Pharmaceutical have Market Authorization of Methyl Salicylate and Sodium Sulfate APIs from NMPA

Hunan Jiudian Pharmaceutical have Market Authorization of dapoxetine hydrochloride, celecoxib and Nicorandil API from NMPA

Hunan Jiudian Pharmaceutical have Market Authorization of Methyl Salicylate and Sodium Sulfate APIs from NMPA

At the beginning of Feb 2025, Jiudian Hongyang's API trimebutine maleate (Y20230000418) officially received the marketing approval from the CDE, and its registration status was successfully changed to "A".

02-10

2025

Jiudian Hongyang's API Trimebutine Maleate Approved for Marketing

Jiudian Pharmaceutical Research Institute successfully completed the annual laboratory instrument maintenance and cleaning

On January 24, under the meticulous planning and coordination of the Quality Control Department of the Drug Research Institute, the annual instrument maintenance and cleaning of the R&D laboratory were successfully completed. The crucial task ensures the efficient and stable operation of laboratory instruments and equipment in the upcoming year, providing robust support for drug research and development.

01-26

2025

Jiudian Pharmaceutical Research Institute successfully completed the annual laboratory instrument maintenance and cleaning

Jiudian Hongyang's pharmaceutical excipients Succinic acid and Calcium hydrogen phosphate dihydrate approved for marketing

Recently, Jiudian Hongyang's pharmaceutical excipients succinic acid (F20220000468) and calcium hydrogen phosphate dihydrate (F20220000396) have officially obtained marketing approval from the Center for Drug Evaluation (CDE), and the registration status of these products has been successfully updated to "A".

01-25

2025

Jiudian Hongyang's pharmaceutical excipients Succinic acid and Calcium hydrogen phosphate dihydrate approved for marketing

Bldg A1, Wukuang Lugu Science and Technology Industry Park, No.28 Lutian Road, Hi-tech development zone, Changsha, Hunan, China TEL. 0086-731-88220222

1

Business license

SEO www.300.cn changsha Privacy policy